Western Blot: 1/500 - 1/1000. Immunohistochemistry: 1/50 - 1/200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
2PP2A antibody, I2PP2A antibody, IGAAD antibody, IPP2A2 antibody, PHAPII antibody, TAF-I antibody, TAF-IBETA antibody, 2610030F17Rik antibody, 5730420M11Rik antibody, AA407739 antibody, I-2PP2A antibody, StF-IT-1 antibody, 2pp2a antibody, i2pp2a antibody, igaad antibody, ipp2a2 antibody, phapii antibody, set antibody, set-a antibody, set-b antibody, taf-ibeta antibody, wu:fb30g11 antibody, wu:fd16c08 antibody, SET nuclear proto-oncogene antibody, SET nuclear oncogene antibody, SET translocation antibody, SET nuclear proto-oncogene L homeolog antibody, SET nuclear proto-oncogene b antibody, SET antibody, Set antibody, LOC403555 antibody, set.L antibody, setb antibody
背景
For gene transcription governed by RNA polymerase I, the human transcription factor SL1 (mouse TIF-IB) directs the assembly of initiation complexes at the prompter. Like TFIID, which directs transcription by RNA polymerase II, SL1/TIF-IB contains the TATA-binding protein (TBP) and a set of TBP-associated factors (TAFs). The three TAF I subunits, hTAF I p110, hTAF I p63 and hTAF p48 (or mouse TAF I p95, TAF I p68 and TAF I p48) are all integral components of SL1/TIF-IB. The mutually exclusive binding of either TAF I or TAF II subunits to TBP is believed to direct the formation of promoter and RNA polymerase-specific complexes.Synonyms: I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I